Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 185345-46-4 | MDL No. : | MFCD21606586 |
Formula : | C7H4BrFO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FSLFKQZWBRMALB-UHFFFAOYSA-N |
M.W : | 219.01 | Pubchem ID : | 18701750 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 41.51 |
TPSA : | 37.3 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.34 cm/s |
Log Po/w (iLOGP) : | 1.39 |
Log Po/w (XLOGP3) : | 1.82 |
Log Po/w (WLOGP) : | 2.53 |
Log Po/w (MLOGP) : | 1.97 |
Log Po/w (SILICOS-IT) : | 2.6 |
Consensus Log Po/w : | 2.06 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.68 |
Solubility : | 0.455 mg/ml ; 0.00208 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.22 |
Solubility : | 1.31 mg/ml ; 0.00598 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -2.91 |
Solubility : | 0.269 mg/ml ; 0.00123 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.38 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
88% | With oxygen; cobalt(II) diacetate tetrahydrate; sodium hydroxide In ethylene glycol at 80℃; for 8 h; | General procedure: a mixture of substrate 1a(1 mmol), cobalt salt (n1molpercent) and NaOH (n2 equiv)in EG (5 mL) was stirred with O2 (1 atm) being bubbled, under 80 oCfor 8 h. Hydrochloric acid (10 mL, 2percent) and methyl tert-butyl ether (MTBE, 10 mL) were successively added to the reactionmixture. The organic layer was separated, and the aqueous phase was furtherextracted with MTBE(10 mL × 2). The combined organic phase was dried over anhydrous sodium sulfateand concentrated to give a residue, which was purified by column chromatographyon silica gel (eluents: petroleum ether/ethyl acetate, 10/1) to provide thedesired products 2a. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
48% | at 45℃; for 26 h; | Intermediate 26. 3-bromo-5-fluoro-4-hydroxybenzaldehyde (26)26; [0198] To a solution of 3-fluoro-4-hydroxybenzaldehyde (2 g, 14.3 mmol, 1 eq, Oakwood Products, Inc., West Columbia, SC, USA) in acetic acid (60 mL), was added a solution of bromine(2.7 g, 17.0 mmol, 1.2 eq) in acetic acid(10 mL), and the mixture was stirred at 45 °C for 26 h. After concentration in vacuo, brine (50 mL) was added to the residue and the mixture was extracted with EtOAc(3 X 80 mL). The combined organic layers were dried (Na2SO4), concentrated in vacuo, and purified by reversed phase semi-preparative .HPLC to afford 1.5 g (48percent) of_3-bromo-5-fluoro-4- hydroxybenzaldehyde (26). |
48% | With bromine In acetic acid at 45℃; for 26 h; | Intermediate 12: 3-bromo-5-fluoro-4-hydroxybenzaldehyde (12)12[0157] To a solution of 3-fluoro-4-hydroxybenzaldehyde (2 g, 14.3 mmol, 1 eq) in acetic acid (60 mL), was added a solution of bromine(2.7 g, 17.0 mmol, 1.2 eq) in acetic acid(10 mL), and the mixture was stirred at 45 °C for 26h. After concentration in vacuo, brine (50 mL) was added to the residue and the mixture was extracted with EtOAc(3 X 80 mL). The combined organic layers were dried (Na2SO4), concentrated in vacuo, and purified by reversed phase semi-preparative .HPLC to afford 1.5 g (48 percent) of_3-bromo-5-fluoro-4-hydroxybenzaldehyde (12). |
[ 178546-34-4 ]
3-Bromo-5-fluoro-2-hydroxybenzaldehyde
Similarity: 0.86
[ 399-00-8 ]
5-Bromo-4-fluoro-2-hydroxybenzaldehyde
Similarity: 0.81
[ 1427438-90-1 ]
4-Bromo-2-fluoro-6-hydroxybenzaldehyde
Similarity: 0.80
[ 1009093-60-0 ]
3-Bromo-5-fluoro-2-methoxybenzaldehyde
Similarity: 0.78
[ 178546-34-4 ]
3-Bromo-5-fluoro-2-hydroxybenzaldehyde
Similarity: 0.86
[ 399-00-8 ]
5-Bromo-4-fluoro-2-hydroxybenzaldehyde
Similarity: 0.81
[ 1427438-90-1 ]
4-Bromo-2-fluoro-6-hydroxybenzaldehyde
Similarity: 0.80
[ 1009093-60-0 ]
3-Bromo-5-fluoro-2-methoxybenzaldehyde
Similarity: 0.78
[ 178546-34-4 ]
3-Bromo-5-fluoro-2-hydroxybenzaldehyde
Similarity: 0.86
[ 399-00-8 ]
5-Bromo-4-fluoro-2-hydroxybenzaldehyde
Similarity: 0.81
[ 1427438-90-1 ]
4-Bromo-2-fluoro-6-hydroxybenzaldehyde
Similarity: 0.80
[ 1009093-60-0 ]
3-Bromo-5-fluoro-2-methoxybenzaldehyde
Similarity: 0.78
[ 178546-34-4 ]
3-Bromo-5-fluoro-2-hydroxybenzaldehyde
Similarity: 0.86
[ 399-00-8 ]
5-Bromo-4-fluoro-2-hydroxybenzaldehyde
Similarity: 0.81
[ 1427438-90-1 ]
4-Bromo-2-fluoro-6-hydroxybenzaldehyde
Similarity: 0.80
[ 1009093-60-0 ]
3-Bromo-5-fluoro-2-methoxybenzaldehyde
Similarity: 0.78